Carmela Ricciardelli
Overview
Explore the profile of Carmela Ricciardelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang W, Lokman N, Barry S, Oehler M, Ricciardelli C
Cancer Metastasis Rev
. 2025 Jan;
44(1):23.
PMID: 39821694
Cancer stem cells play an important role in tumor progression and chemotherapy resistance. Leucine-rich G repeat-containing protein-coupled receptor 5 (LGR5) has been identified as a cancer stem cell marker in...
2.
Davies L, Ganesen R, Toubia J, Hong S, Kumar Kc S, Oehler M, et al.
Mol Oncol
. 2024 Dec;
PMID: 39626867
High-grade serous ovarian cancer (HGSOC) is the most common and aggressive type of ovarian cancer. Due to a lack of an early detection test and overt symptoms, many patients are...
3.
Fujimoto H, Yoshihara M, Ricciardelli C, Tano S, Iyoshi S, Miyamoto E, et al.
Sci Rep
. 2024 Oct;
14(1):23537.
PMID: 39384823
Ovarian cancer (OvCa) is one of the most lethal gynecological malignancies, and most patients are diagnosed at advanced stage with peritoneal dissemination. Although age at diagnosis is considered an independent...
4.
Khetan R, Eldi P, Lokman N, Ricciardelli C, Oehler M, Blencowe A, et al.
J Ovarian Res
. 2024 Jul;
17(1):156.
PMID: 39068454
Genetic heterogeneity in ovarian cancer indicates the need for personalised treatment approaches. Currently, very few G-protein coupled receptors (GPCRs) have been investigated for active targeting with nanomedicines such as antibody-conjugated...
5.
Bandara V, Niktaras V, Willett V, Chapman H, Lokman N, Macpherson A, et al.
Clin Transl Immunology
. 2024 May;
13(5):e1512.
PMID: 38800555
Objectives: Recent studies have identified expression of the non-functional P2X7 (nfP2X7) receptor on various malignant cells including ovarian cancer, but not on normal cells, which makes it a promising tumour-associated...
6.
Fujimoto H, Yoshihara M, Rodgers R, Iyoshi S, Mogi K, Miyamoto E, et al.
Cancer Metastasis Rev
. 2024 Mar;
43(3):1037-1053.
PMID: 38546906
Epithelial ovarian cancer (EOC) is often diagnosed in advanced stage with peritoneal dissemination. Recent studies indicate that aberrant accumulation of collagen fibers in tumor stroma has a variety of effects...
7.
Price Z, Lokman N, Sugiyama M, Koya Y, Yoshihara M, Oehler M, et al.
Cell Mol Life Sci
. 2023 Oct;
80(11):320.
PMID: 37815603
Although the pro-tumorigenic functions of hyaluronan (HA) are well documented there is limited information on the effects and targets of different molecular weight HA. Here, we investigated the effects of...
8.
Khan S, Lokman N, Oehler M, Ricciardelli C, Yool A
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760476
Aquaporin (AQP) channels in endometrial cancer (EC) cells are of interest as pharmacological targets to reduce tumor progression. A panel of compounds, including AQP1 ion channel inhibitors (AqB011 and 5-(phenoxymethyl)...
9.
Bandara V, Foeng J, Gundsambuu B, Norton T, Napoli S, McPeake D, et al.
Nat Commun
. 2023 Sep;
14(1):5546.
PMID: 37684239
Chimeric antigen receptor (CAR)-T cell immunotherapy is a novel treatment that genetically modifies the patients' own T cells to target and kill malignant cells. However, identification of tumour-specific antigens expressed...
10.
Arentz G, Mittal P, Klingler-Hoffmann M, Condina M, Ricciardelli C, Lokman N, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046833
Eighty percent of ovarian cancer patients initially respond to chemotherapy, but the majority eventually experience a relapse and die from the disease with acquired chemoresistance. In addition, 20% of patients...